Skip to content
About Us
Team
Programs and Pipeline
Menu Toggle
Summary and Pipeline
SerpinPC
Orexin Receptor 2 Agonist Program
LockBody® Technology Platform
Investors
News
Careers
Main Menu
About Us
Team
Programs and Pipeline
Menu Toggle
Summary and Pipeline
SerpinPC
Orexin Receptor 2 Agonist Program
LockBody® Technology Platform
Investors
News
Careers
About Us
Team
Programs and Pipeline
Menu Toggle
Summary and Pipeline
SerpinPC
Orexin Receptor 2 Agonist Program
LockBody® Technology Platform
Investors
News
Careers
Main Menu
About Us
Team
Programs and Pipeline
Menu Toggle
Summary and Pipeline
SerpinPC
Orexin Receptor 2 Agonist Program
LockBody® Technology Platform
Investors
News
Careers
Patient-Centric
Mission.
Asset-Centric
Approach.
We’re pursuing our
Orexin Receptor 2 Agonist Program
to bring potentially transformative treatment options to patients with sleep-wake disorders.
Patient-Centric
Mission.
Asset-Centric
Approach.
We’re pursuing
SerpinPC
as a potential novel subcutaneous treatment for hemophilia B patients with potential expansion into other bleeding disorders.
Patient-Centric
Mission.
Asset-Centric
Approach.
We’re pursuing our
LockBody® Technology Platform
with the aim to redefine immuno-oncology treatment for patients with cancer.
We are leaders, innovators, and scientists aiming to pursue medicines that are transformational for patients.
Team
Latest News
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
News
Scroll to Top